Begin main content

Tecentriq for Non-Small Cell Lung Cancer – Details

Project Number pCODR 10115
Brand Name Tecentriq
Generic Name Atezolizumab
Tumour Type Lung
Indication Non-Small Cell Lung Cancer
Funding Request For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit
Review Status Under Review
Pre Noc Submission Yes
NOC Date
Manufacturer Hoffmann-La Roche Limited
Submitter Hoffmann-La Roche Limited
Submission Date December 15, 2017
Submission Deemed Complete December 22, 2017
Submission Type New Drug
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ January 8, 2018
Check-point meeting February 13, 2018
pERC Meeting (target date) May 17, 2018
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.